Iglesias JF et al.Cardiovasc Revasc Med. 2022 Jan;34:3-10. 

在急性冠脉综合征（ACS）患者中，与耐用聚合物-依维莫司洗脱支架(DP-EES)相比生物降解聚合物-西罗莫司洗脱支架(BP-SES)可以降低靶病变失败率(TLF)

该项研究纳入2119例患者，1131例患者(53%)出现ACS，5年累积TLF发生率明显低于慢性冠脉综合征患者[16.5% vs. 22.9%；RR， 0.69；95%CI，0.57- 0.85;p ＜0.001]。5年后，接受BP-SES和DP-EES治疗的ACS患者TLF发生率相似(16.9% vs. 16.0%；RR 1.04；95% CI，0.78 1.41;p = 0.78)

在BIOSCIENCE试验的亚组分析中，我们发现接受BP-SES或DP-EES治疗的ACS或CCS患者中，5年中TLF治疗效果一致。在ACS患者中，BP-SES和DP-EES在5年随访期间的长期临床结果没有显著差异。

Abstract

Background: Thin-strut biodegradable polymer sirolimus-eluting stents (BP-SES) have been shown to reduce target lesion failure (TLF) at one-year follow-up compared with durable polymer everolimus-eluting stents (DP-EES) among patients with acute coronary syndrome (ACS). The long-term clinical benefits of thin-strut BP-SES over DP-EES in ACS patients after complete degradation of the polymer coating remain uncertain.

Methods: We performed a post-hoc subgroup analysis of ACS patients included into the BIOSCIENCE randomized trial (NCT01443104). The primary endpoint was target lesion failure (TLF), a composite of cardiac death, target-vessel myocardial infarction or clinically indicated target lesion revascularization, at 5 years.

Results: Among 2119 patients enrolled between March 2012 and May 2013, 1131 (53%) presented with ACS. The 5-year cumulative incidence of TLF was significantly lower in patients with ACS compared to chronic coronary syndrome [16.5% vs. 22.9%; rate ratio (RR), 0.69; 95% confidence interval (CI), 0.57-0.85; p < 0.001]. At 5 years, TLF occurred similarly in ACS patients treated with BP-SES and DP-EES (16.9% vs. 16.0%; RR, 1.04; 95% CI, 0.78-1.41; p = 0.78). The individual components of the primary endpoint did not differ between ACS patients treated with BP-SES or DP-EES at 5 years. Overall, there was no interaction between clinical presentation and treatment effect.

Conclusions: In a subgroup analysis of the BIOSCIENCE trial, we found no difference in long-term outcomes between ACS patients treated with BP-SES or DP-EES at 5 years.

百度浏览   来源 : 医微客   

版权声明：本网站所有注明来源“医微客”的文字、图片和音视频资料，版权均属于医微客所有，非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源：”医微客”。本网所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，转载仅作观点分享，版权归原作者所有。不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。 本站拥有对此声明的最终解释权。